Plasma beta-endorphin levels and glucose tolerance in patients with chronic renal failure

Biomed Pharmacother. 1995;49(6):283-7. doi: 10.1016/0753-3322(96)82644-8.

Abstract

In order to examine the role of endogenous opioid peptides on glucose metabolism in uraemic patients, plasma concentrations of beta-endorphin, glucose, insulin and C-peptide were determined before and during an oral glucose tolerance test (OGTT) in nine non-dialysed patients with chronic renal failure (CRF). The results are compared with those obtained in a group of age-matched normal subjects. In CRF patients, plasma beta-endorphin fasting values (16.0 +/- 1.9 pmol/l) were significantly higher than those of the controls (6.6 +/- 0.6 pmol/l) and significantly correlated with the degree of renal function impairment. After glucose load, plasma beta-endorphin in CRF patients tended to decline, whereas in normal subjects increased. The fasting and the mean OGTT plasma beta-endorphin values negatively correlated with insulin initial response to glucose, insulin and C-peptide mean OGTT values, but not with glucose OGTT mean values. Data indicate that chronic uraemia induces a significant increase in circulating plasma beta-endorphin levels, with a loss of opioid system responsiveness to glucose. The possibility that this hyper-endorphinism may have a biological importance at least as a contributory factor of impaired glucose tolerance in uraemia may be suggested.

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / analysis
  • C-Peptide / blood
  • Fasting
  • Female
  • Glucose Tolerance Test
  • Humans
  • Insulin / blood
  • Kidney Failure, Chronic / blood*
  • Male
  • Middle Aged
  • beta-Endorphin / blood*

Substances

  • Blood Glucose
  • C-Peptide
  • Insulin
  • beta-Endorphin